How did Apellis' revenue and expenses trend in Q4 2024?

Apellis Pharmaceuticals (APLS) experienced a significant decline in net income, with a reported $36.35 million loss in Q4 2024, while total revenues remained stable at approximately $709.95 million. The company's focus on product sales and licensing agreements contributed to the revenue base, with product-related revenue at $518.78 million and licensing revenue at $71.41 million. Total expenses were $212.53 million, which, when combined with the net loss, indicate a challenging financial period for the company. |code|Ticker|Name|Date|Business Composition|Revenue By Business|market_code| |---|---|---|---|---|---|---| |APLS|APLS.O|Apellis|20240101-2024|Licensing|7.1413E7|185| |APLS|APLS.O|Apellis|20240101-2024|Licensing|5.0057E7|185| |APLS|APLS.O|Apellis|20240101-2024|Licensing|2.9798E7|185| |APLS|APLS.O|Apellis|20240101-2024|Licensing|9250000|185| |APLS|APLS.O|Apellis|20240101-2024|Product|1.63075E8|185| |APLS|APLS.O|Apellis|20240101-2024|Licensing|9250000|185| |code|Ticker|Name|Date|Net Income YoY|Net Income|market_code| |---|---|---|---|---|---|---| |APLS|APLS.O|Apellis|2024 Q1|62.63710920361349|-6.6423E7|185| |APLS|APLS.O|Apellis|2024 Q2|69.14296483853258|-3.7657E7|185| |APLS|APLS.O|Apellis|2024 Q3|59.037201309212264|-5.7445E7|185| |APLS|APLS.O|Apellis|2024 Q4|58.9584085982659|-3.6353E7|185| |code|Ticker|Name|Date|Total Revenue YoY|Total Revenue|market_code| |---|---|---|---|---|---|---| |APLS|APLS.O|Apellis|2024 Q1|284.25946572715515|1.72325E8|185| |APLS|APLS.O|Apellis|2024 Q2|110.26334909286189|1.99685E8|185| |APLS|APLS.O|Apellis|2024 Q3|78.28965842081902|1.9683E8|185| |APLS|APLS.O|Apellis|2024 Q4|45.19220915854267|2.12528E8|185|